| Company Name: |
Musechem |
| Tel: |
+1-800-259-7612 |
| Email: |
info@musechem.com |
| Company Name: |
Twochem Co.Ltd. |
| Tel: |
021-58111628 15800915896 |
| Email: |
sales@twochem.com |
KX2-391 (Mesylate) manufacturers
|
| | KX2-391 (Mesylate) Basic information |
| Product Name: | KX2-391 (Mesylate) | | Synonyms: | Tirbanibulin Mesylate;KX01 MESYLATE;KX2-391 (Mesylate);2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide mesylate;KX01,KX2-391,Src,Tirbanibulin Mesylate,Inhibitor,inhibit,KX-01,Tirbanibulin,KX 01,Microtubule/Tubulin;Tirbanibulin Mesylate, 10 mM in DMSO | | CAS: | 1080645-95-9 | | MF: | C27H33N3O6S | | MW: | 527.63242 | | EINECS: | | | Product Categories: | | | Mol File: | 1080645-95-9.mol |  |
| | KX2-391 (Mesylate) Chemical Properties |
| storage temp. | Store at -20°C, protect from light, stored under nitrogen | | solubility | DMSO : ≥ 57 mg/mL (108.03 mM) | | form | Solid | | color | White to off-white |
| | KX2-391 (Mesylate) Usage And Synthesis |
| Uses | Tirbanibulin Mesylate (KX2-391 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. | | in vivo | Orally administered Tirbanibulin Mesylate (KX2-391 Mesylate) is shown to inhibit primary tumor growth and to suppress metastasis, in pre-clinical animal models of cancer[2]. | | References | [1] Lau GM, et al. Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci, 2009, 54(7), 1465-1474. DOI:10.1007/s10620-008-0519-0
[2] Fallah-Tafti A, et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem, 2011, 46(10), 4853-4858. DOI:10.1016/j.ejmech.2011.07.050 |
| | KX2-391 (Mesylate) Preparation Products And Raw materials |
|